Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies


Honey, E; Augood, C; Templeton, A; Russell, I; Paavonen, J; Mardh, PA; Stary, A; Stray-Pedersen, B; (2002) Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sexually transmitted infections, 78 (6). pp. 406-412. ISSN 1368-4973 DOI: https://doi.org/10.1136/sti.78.6.406

Full text not available from this repository.

Abstract

Objective: Screening for Chlamydia trachomatis in the lower genital tract may contribute to the prevention of pelvic inflammatory disease in women. The purpose of this review was to critically appraise, and summarise studies of the cost effectiveness of screening for C trachomatis. Methods: A literature search was conducted on Medline and in Health Star from 1990-2000. Keywords were C trachomatis, screening, cost effectiveness. Bibliographies of reviewed articles were also searched. The population studied was asymptomatic sexually active women under 30 years of age in a primary care setting. The intervention assessed was screening for lower genital tract infection with C trachomatis and the outcomes studied were cases of C trachomatis detected, cases of PID prevented, and associated costs. Studies were assessed using the Drummond criteria for economic evaluations. They were assessed qualitatively as they were too heterogeneous to allow quantitative analysis. Results: 10 studies were included. All were modelled scenarios and all found screening to be more cost effective than simply testing symptomatic women, although all were based on probabilities that were assumed. Six of the studies focused on DNA based testing, three of them using urine. The models showed screening to be cost effective at prevalences of 3.1-10.0%, and cost saving (overtesting symptomatic women) at a prevalence as low as 1.1%, if age was used as a selection factor and DNA based tests were used in urine samples. Conclusions: At the prevalence of infection expected in the target population, all studies suggest screening is cost effective. However, the assumptions used in the models have been difficult to confirm and there is a need for more data, particularly on the risk of complications in women with asymptomatic lower tract infection.

Item Type: Article
Keywords: Chlamydia Infections, diagnosis, economics, Chlamydia trachomatis, Cost-Benefit Analysis, Female, Humans, Mass Screening, economics, Randomized Controlled Trials as Topic
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
PubMed ID: 12473799
Web of Science ID: 179999000005
URI: http://researchonline.lshtm.ac.uk/id/eprint/5994

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
301Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item